European Alpha-1 Awareness Day; European Health Made National (25 April 2018)
25 APRIL – EUROPEAN ALPHA-1 AWARENESS DAY
European Health Made National
Rare diseases are often a neglected issue because of their relatively low prevalence. The burden of such conditions is not about numbers, but about an individual’s life which can be significantly impacted by delayed diagnosis and limited access to treatment. Alpha-1 Antitrypsin Deficiency (AATD) is one of those rare conditions that can significantly impair health and be life-threatening.
Without proper treatment and care patients can have a decreased life expectancy and suffer from severe shortness of breath, immobility, recurrent hospital admissions and may eventually require lung transplantation. In addition to causing serious lung disease in adults, AATD can also cause life-threatening liver damage in adults and children that may also require liver transplantation and more rarely a disfiguring skin condition.
On 25 April 2018, the first European Alpha-1 Awareness Day will be celebrated to raise further understanding about this genetic condition. AATD is most common in individuals of Northern European and Iberian descent. Despite its prevalence in Europe, patients and healthcare providers continue to be poorly informed about the disorder, and an overwhelming number of individuals are therefore not correctly diagnosed as Alpha-1 patients.
Alpha-1 currently has no cure, however, there are treatments developed for better disease management. One of the most progressive treatments for Alpha-1 lung and skin affected patients is plasma derived therapy to restore the normal level of AAT, which slows down progression of lung damage and heals the skin condition panniculitis. National policies on Alpha-1 diagnosis, treatment and care vary across Europe, as each country has its own healthcare system and policy for rare diseases. Despite promising results and cost-effectiveness of augmentation therapy, there are only a few countries that reimburse the treatment.
This inequality is evident for example in the Netherlands, where augmentation therapy is reimbursed only for a selected group of AATD patients. In Belgium the reimbursement stopped several years ago, leaving those Alpha-1 patients diagnosed after June 2010 without treatment. In Poland, Alpha-1 patients do not have access to augmentation therapy and face limitations to correct diagnosis and care.
Without a timely diagnosis and appropriate treatment, the life of many patients is at risk. Currently, AATD is a largely underrecognized, and thus, an underdiagnosed condition, requiring immediate action by the Member States’ governments to improve the lives of affected individuals.
In conjunction with the European Alpha-1 Awareness Day and through the European Alpha-1 Expert Group Recommendations, the following is provided:
- All Member States should develop an Alpha-1 diagnosis programme in their rare disease plan. The European Commission should develop a project to generate minimum credentials for Alpha-1 centres of excellence.
- National paying agencies should develop reimbursement decisions by distinguishing Alpha-1 patients who are either those with rapid or non-declining lung function.
- National governments should ensure that legislation does not deter individuals from genetic testing for rare diseases by ensuring that non-symptomatic patients do not have higher insurance premiums.
Recommendations for Healthcare Professionals (HCP)
- HCPs should consider a diagnosis of Alpha-1 in patients with COPD, emphysema, adult onset bronchial asthma, bronchiectasis, unexplained liver disease, panniculitis, unexpected vasculitis and any patients with a family history of Alpha-1.
- Centres of excellence should work through networks such as the European Reference Networks to share expertise, refer patients and educate healthcare professionals across Europe.
Recommendations for Individuals and Carers
- If you have unexplained symptoms of lung, liver or skin disease, ask your doctor to be tested for Alpha-1.
- Alpha-1 patients should adjust their lifestyles to reduce the chance of the onset, or aggravation of lung, liver or skin disease.
- Alpha-1 patients and carers should seek support from the patient and/or support groups.
Events to take place in Brussels, related to the European Alpha-1 Awareness Day
24 April 2018 (15:00 – 17:00)
Roundtable Discussion “European Alpha-1 Awareness Day: European Health Made National”
European Parliament – Brussels, Room A5F385
Hosted by Marek Plura MEP, EPP – Poland
To register: email@example.com
25 April 2018 (9.30-12.00)
EU AATD Roundtable (Event organized by CSL Behring. Attendance by invitation only.)
Martin’s Brussels EU Hotel